The tweet was deleted by the author.
But we saved everything 🙂.
Allogene Therapeutics is advancing its investigational AlloCAR T products as it seeks to redefine the CAR T cell therapy landscape.
The company highlights the potential of allogeneic, or off-the-shelf, cell therapies to enable greater speed, scalability, and patient access compared to autologous treatments. This next-generation approach aims to address key bottlenecks that have limited broader use of CAR T cell therapy for patients in need.
View post on X Loading...
Allogene has previously addressed early ALPHA3 safety data and reviewed the use of investigational cema-cel for MRD-positive LBCL outpatients in a recent update (article). The company also launched the ALPHA3 trial using MRD testing to target relapse in LBCL patients (article). These efforts highlight its ongoing development of allogeneic CAR T treatments.